ArticleRSC advances2025
Dual-emission nitrogen-doped carbon dots for ratiometric and smartphone-based detection of levofloxacin.
Article in RSC advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Levofloxacin (LEV) is a third-generation fluoroquinolone commonly applied in treatment against infections in both humans and animals. However, its overuse has led to increasing concerns regarding environmental contamination, health risks, and the emergence of antibiotic-resistant bacteria. In this study, we present a novel dual-emission ratiometric fluorescence probe for the detection of LEV, utilizing the intrinsic green fluorescence of LEV as the sensing signal and blue-emissive nitrogen-doped carbon dots (N-CDs) as an internal reference. N-CDs were synthesized
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.